307 related articles for article (PubMed ID: 15648082)
1. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
[TBL] [Abstract][Full Text] [Related]
2. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Postma R; Roobol M; Schröder FH; van der Kwast TH
Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
[TBL] [Abstract][Full Text] [Related]
3. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
4. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
6. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
[TBL] [Abstract][Full Text] [Related]
7. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
9. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
12. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
[TBL] [Abstract][Full Text] [Related]
13. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
14. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
Zackrisson B; Aus G; Bergdahl S; Lilja H; Lodding P; Pihl CG; Hugosson J
J Urol; 2004 Apr; 171(4):1500-3. PubMed ID: 15017207
[TBL] [Abstract][Full Text] [Related]
15. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Yan Y; Carvalhal GF; Catalona WJ; Young JD
Cancer; 2000 Mar; 88(5):1122-30. PubMed ID: 10699903
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
17. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
19. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
20. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
